Netherlands-based biotechnology company VectorY Therapeutics has raised 129 million euros, or $138 million, to fund development of brain disease drugs.
The Series A financing, announced Monday, was co-led by venture capital firm Forbion and European investor EQT Life Sciences, alongside new backers that included Merck & Co’s venture arm and the ALS Investment Fund.
According to Forbion, VectorY’s financing is one of the largest funding rounds for a private biotech in Europe this year.
